Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: An early marker of resistance to immune control?

British Journal of Dermatology

Volumn 171, Issue 5, 2014, Pages 987-995

  Chevolet, I ^a   Speeckaert, R ^a   Haspeslagh, M ^a   Neyns, B ^a   Kruse V ^b   Schreuer, M ^a   Van Gele, M ^a   Van Geel, N ^a   Brochez, L ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; INDOLEAMINE 2,3 DIOXYGENASE; TRANSCRIPTION FACTOR FOXP3; TUMOR MARKER;

ADULT; AGE; ARTICLE; BRESLOW THICKNESS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN-TRANSIT METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; METASTATIC MELANOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY TUMOR; PROTEIN EXPRESSION; SENTINEL LYMPH NODE; SEX; STROMA; THICKNESS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR INVASION; ULCER; ENDOTHELIUM CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PROGNOSIS; SKIN TUMOR; TUMOR ESCAPE;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL;

EID: 84911414063     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13100     Document Type: Article

References (34)

1. Taylor MW, Feng GS,. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991; 5: 2516-22.
2. Munn DH, Zhou M, Attwood JT, et al,. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-3.
3. Guillonneau C, Hill M, Hubert FX, et al,. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117: 1096-106.
4. Thebault P, Condamine T, Heslan M, et al,. Role of IFNgamma in allograft tolerance mediated by CD4+CD25+ regulatory T cells by induction of IDO in endothelial cells. Am J Transplant 2007; 7: 2472-82.
5. Zou W,. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-74.
6. Johnson TS, Munn DH,. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunol Invest 2012; 41: 765-97.
7. Speeckaert R, Vermaelen K, van Geel N, et al,. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur J Cancer 2012; 48: 2001-11.
8. Brandacher G, Perathoner A, Ladurner R, et al,. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006; 12: 1144-51.
9. Ino K, Yamamoto E, Shibata K, et al,. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 2008; 14: 2310-17.
10. Ino K, Yoshida N, Kajiyama H, et al,. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006; 95: 1555-61.
11. Chamuleau ME, van de Loosdrecht AA, Hess CJ, et al,. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica 2008; 93: 1894-8.
12. Brody JR, Costantino CL, Berger AC, et al,. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 2009; 8: 1930-4.
13. Ferdinande L, Decaestecker C, Verset L, et al,. Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. Br J Cancer 2012; 106: 141-7.
14. Riesenberg R, Weiler C, Spring O, et al,. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res 2007; 13: 6993-7002.
15. Jacquemier J, Bertucci F, Finetti P, et al,. High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. Int J Cancer 2012; 130: 96-104.
16. Munn DH, Sharma MD, Lee JR, et al,. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297: 1867-70.
17. Mellor AL, Chandler P, Baban B, et al,. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 2004; 16: 1391-401.
18. Ji RR, Chasalow SD, Wang LS, et al,. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012; 61: 1019-31.
19. Hamid O, Schmidt H, Nissan A, et al,. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011; 9: 204.
20. Clemente CG, Mihm MC Jr, Bufalino R, et al,. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303-10.
21. Miwa N, Hayakawa S, Miyazaki S, et al,. IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-gamma increase in normal pregnancy but decrease in spontaneous abortion. Mol Hum Reprod 2005; 11: 865-70.
22. Piras F, Colombari R, Minerba L, et al,. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 2005; 104: 1246-54.
23. Hussein MR,. Tumour-infiltrating lymphocytes and melanoma tumorigenesis: an insight. Br J Dermatol 2005; 153: 18-21.
24. Gerber AL, Munst A, Schlapbach C, et al,. High expression of FOXP3 in primary melanoma is associated with tumour progression. Br J Dermatol 2014; 170: 103-9.
25. Prendergast GC, Metz R, Muller AJ,. IDO recruits Tregs in melanoma. Cell Cycle 2009; 8: 1818-19.
26. Lob S, Konigsrainer A, Rammensee HG, et al,. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 2009; 9: 445-52.
27. Holmgaard RB, Zamarin D, Munn DH, et al,. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 2013; 210: 1389-402.
28. Herbert A, Ng H, Jessup W, et al,. Hypoxia regulates the production and activity of glucose transporter-1 and indoleamine 2,3-dioxygenase in monocyte-derived endothelial-like cells: possible relevance to infantile haemangioma pathogenesis. Br J Dermatol 2011; 164: 308-15.
29. Zhang G, Liu WL, Zhang L, et al,. Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma. Clin Dev Immunol 2011; 2011: 384726.
30. Gajewski TF,. Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol 2011; 38: 236-42.
31. Spranger S, Spaapen RM, Zha Y, et al,. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med 2013; 5: 200ra116.
32. Uyttenhove C, Pilotte L, Theate I, et al,. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9: 1269-74.
33. Ascierto PA, Kalos M, Schaer DA, et al,. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013; 19: 1009-20.
34. Huang TT, Yen MC, Lin CC, et al,. Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer. Cancer Sci 2011; 102: 2214-20.